GlassScriptPhysician profile
Michael P Ridge
NPI 1689660813
$2,137.06
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.05 · 2020: $239 · 2021: $793 · 2022: $681 · 2023: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.68 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $145.77 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $126.42 | 2021-2023 | |
| Lilly USA, LLC | $117.15 | 2020-2023 | Jardiance, Emgality |
| Glaxosmithkline, LLC. | $97.53 | 2019-2023 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $81.67 | 2020-2022 | |
| Astellas Pharma US INC | $57.71 | 2019-2021 | |
| Pfizer INC. | $57.65 | 2019-2023 | |
| Novo Nordisk INC | $54.19 | 2020-2023 | Rybelsus |
| Nestle Healthcare Nutrition INC. | $34.85 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $31.39 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $28.60 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $27.97 | 2021 | |
| Silk Road Medical, INC. | $27.93 | 2020 | |
| Janssen Pharmaceuticals, INC | $27.02 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $24.21 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $21.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.39 | 2020 | |
| Allergan, INC. | $17.24 | 2020 | |
| Abbott Laboratories | $16.95 | 2021 | |
| Almatica Pharma LLC | $16.13 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.06 | 2023 | Opsumit |
| Grifols USA, LLC | $14.59 | 2021 | |
| Cranial Technologies, INC | $14.38 | 2021 | |
| Itamar Medical INC | $13.15 | 2022 | |
| Lucid Diagnostics INC. | $12.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.